XORTX Therapeutics
XRTX
4 hedge funds and large institutions have $66K invested in XORTX Therapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
27.47% less ownership
Funds ownership: 27.64% → 0.17% (-27%)
100% less capital invested
Capital invested by funds: $161M → $66K (-$161M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$47K |
| 2 |
JP Morgan Chase
New York
|
+$799 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$161M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Bank of Montreal
Toronto,
Ontario, Canada
| $59.8K | +$47K | +2,999 | New |
|
2
Osaic Holdings
Scottsdale,
Arizona
| $4.27K | – | – | – |
|
|
3
JP Morgan Chase
New York
| $1.21K | +$799 | +51 | New |
|
|
CA
4
Clearstead Advisors
Cleveland,
Ohio
| $696 | – | – | – |
|
|
5
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
| – | -$161M | -552,418 | Closed |
|
|
6
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -105 | Closed |
|
XRTX Hedge Fund Activity: Q1 2024 in Review
4 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q1 2024, worth a combined $66K — down 100% from $161M a quarter earlier.
Fund positioning in XRTX was balanced in Q1 2024: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Bank of Montreal, opening a new position worth an estimated $47K. The largest seller was DekaBank Deutsche Girozentrale, exiting entirely with an estimated $161M sold.
- 4 institutional investors held XORTX Therapeutics (XRTX) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $66K of XORTX Therapeutics stock for Q1 2024, down 100% quarter-over-quarter.
- 2 funds opened new XORTX Therapeutics positions in Q1 2024 and 2 closed out, a net change of 0 holders.
- The largest XORTX Therapeutics buyer in Q1 2024 was Bank of Montreal, an estimated $47K added.
- The largest XORTX Therapeutics seller in Q1 2024 was DekaBank Deutsche Girozentrale, an estimated $161M sold.
Based on aggregated 13F filings for Q1 2024.